Chronic Hepatitis B Market By Drug Class, By Gender, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Antivirals
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Immune Modulators
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country

CHAPTER 5: CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER
5.1 Overview
5.1.1 Market size and forecast
5.2 Male
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.2.4 Male Chronic Hepatitis B (CHB) Market by Age Group
5.2.4.1 Adult Market size and forecast, by region
5.2.4.2 Geriartic Market size and forecast, by region
5.3 Female
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.3.4 Female Chronic Hepatitis B (CHB) Market by Age Group
5.3.4.1 Adult Market size and forecast, by region
5.3.4.2 Geriartic Market size and forecast, by region

CHAPTER 6: CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: CHRONIC HEPATITIS B (CHB) MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.3 North America Market size and forecast, by Gender
7.2.3.1 North America Male Chronic Hepatitis B (CHB) Market by Age Group
7.2.3.2 North America Female Chronic Hepatitis B (CHB) Market by Age Group
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Gender
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Gender
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Gender
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.3 Europe Market size and forecast, by Gender
7.3.3.1 Europe Male Chronic Hepatitis B (CHB) Market by Age Group
7.3.3.2 Europe Female Chronic Hepatitis B (CHB) Market by Age Group
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Gender
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Gender
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Gender
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Gender
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Gender
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Gender
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.3 Asia-Pacific Market size and forecast, by Gender
7.4.3.1 Asia-Pacific Male Chronic Hepatitis B (CHB) Market by Age Group
7.4.3.2 Asia-Pacific Female Chronic Hepatitis B (CHB) Market by Age Group
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Gender
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Gender
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Gender
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Gender
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Gender
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Gender
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.3 LAMEA Market size and forecast, by Gender
7.5.3.1 LAMEA Male Chronic Hepatitis B (CHB) Market by Age Group
7.5.3.2 LAMEA Female Chronic Hepatitis B (CHB) Market by Age Group
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Gender
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Gender
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Gender
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Gender
7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 GlaxoSmithKline (GSK)
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Gilead Sciences, Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Merck & Co. Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Bristol Myers Squibb Co.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Teva Pharmaceutical Industries Limited
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 zydus cadila
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novartis AG
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 F. Hoffman La Roche, Ltd.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Viatris Inc. (Mylan NV)
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Cipla Ltd
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Chronic Hepatitis B (CHB) Market,' the chronic hepatitis b (CHB) market was valued at $4.6 billion in 2021, and is estimated to reach $6.2 billion by 2031, growing at a CAGR of 3% from 2022 to 2031.

Hepatitis B is a viral infection that causes liver inflammation and damage. Inflammation is swelling that occurs when tissues of the body become injured or infected. Inflammation can damage organs. Chronic hepatitis B is a long-lasting infection. According to National Institutes of Health (NIH), about 90% of infants infected with hepatitis B develop a chronic infection. About 25 to 50% of children infected between the ages of 1 and 5 years develop chronic infections. However, only about 5% of people first infected as adults develop chronic hepatitis B.

The surge in the prevalence of hepatitis B and improvements in healthcare infrastructure drive the growth of the Chronic Hepatitis B Market Size. For instance, in April 2022, according to Bristol Myers & Squibb, each year, nearly 1 million people worldwide died due to hepatitis B or hepatitis c. In addition, rise in awareness about hepatitis infection and advancements in hepatitis treatment boost the expansion of the Chronic Hepatitis B Industry.

The strict government regulations on blood transfusion and blood banks contribute to the growth of the Chronic Hepatitis B Market Size. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis c, and syphilis should be mandatory. and initiatives taken by the government and non-government organizations propel the growth of the Chronic Hepatitis B Market Size.

Furthermore, Chronic Hepatitis B Market Trends that drive the growth of the chronic hepatitis B market include R&D for the development of chronic hepatitis B, an increase in drug class approvals, and new product launches in the market. In addition, advancements in the diagnosis of hepatitis B propel the growth of the market. For instance, in May 2022, Abbott, a leading pharmaceutical company, announced the launch of HBsAg Next Qualitative Assay for early detection of the Hepatitis B virus (HBV) in India. Early identification of HBV infections not only helps in preventing or delaying the progression of advanced liver diseases but also reduces the risk of transmission. Furthermore, the rise in healthcare expenditure and improvements in healthcare facilities in developing nations contribute to the growth of the Chronic Hepatitis B Industry.

The chronic hepatitis B market is segmented into drug class, gender, distribution channel, and region.

Based on the drug class segment, the market is divided into antivirals and immune modulators. The antivirals segment dominated the Chronic Hepatitis B Market Share in 2021, and this trend is expected to continue during the Chronic Hepatitis B Market Forecast period, owing to the increase in the prevalence of hepatitis B.

Based on gender segment, the market is categorized into male and female. The male segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to the high prevalence rate of male and an increase in blood transfusion rate.

Depending on the distribution channel segment, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to an increase in healthcare expenditure and a rise in the number of drug stores & retail pharmacies.

North America accounted for a majority of the global chronic hepatitis B market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to the rising prevalence of hepatitis B, the well-established healthcare infrastructure, and the presence of key players in the region. Asia-Pacific is anticipated to witness lucrative growth during the Chronic Hepatitis B Market Analysis period owing to an increase in the number of blood banks, growth in the geriatric population, and a high population base.

Key findings of the study

By drug class, the antivirals segment was the highest contributor to the Chronic Hepatitis B (CHB) Market in 2021.

By gender, the male segment was the highest contributor to the Chronic Hepatitis B (CHB) Market in 2021.

By distribution channel, the drug stores & retail pharmacies segment was the highest contributor to the market in 2021.

Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period

Companies Mentioned

• GlaxoSmithKline (Gsk)
• Gilead Sciences, Inc.
• Merck & Co. Inc.
• Bristol Myers Squibb Co.
• Teva Pharmaceutical Industries Limited
• Zydus Cadila
• Novartis AG
• F. Hoffman La Roche, Ltd.
• Viatris Inc. (Mylan Nv)
• Cipla Ltd

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.